Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04947280
Other study ID # FDRT-BC012
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date January 1, 2021
Est. completion date December 31, 2026

Study information

Verified date April 2021
Source Fudan University
Contact Zhaozhi Yang, MD, Ph.D
Phone 8618017317126
Email yzzhi2006@yahoo.com.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Fractionated stereotatic radiation therapy (FSRT) that very precisely delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. The purpose of this study is to find out if FSRT is safe and effective in the treatment of metastatic spinal tumors of breast cancer.


Description:

Eligible breast cancer patients with bone metastases will be treated with FSRT. 9-10 Gy x 3Fx or 6-7 Gy x 5Fx image-guided fractionated stereotatic radiation therapy will be used.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date December 31, 2026
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: 1. Diagnosis of invasive breast cancer 2. Signed informed consent 3. Bone metastases (confirmed by MRI within 4 weeks of enrollment). 4. Paraosseous soft tissue = 5cm. The tumour could involve the vertebral column, but did not have to, nor did it need to enter the spinal canal. 5. KPS = 40 or ECOG 0-2. 6. The tumor is at least 2 mm away from the spinal cord. If the tumor is closer than 2 mm, surgical resection is required prior to FSRT or the total prescription dose of spinal cord is strictly limited. 7. Failure of previous conventional external beam radiotherapy or surgery, residual tumor after surgery, medical inoperability, and refusal to undergo surgery. 8. A maximum of three distinct noncontiguous spinal metastases per patient was allowed, and each of the separate sites may have involvement of 2 contiguous vertebral bodies. 9. Patients have sufficient bone marrow reserve and liver and kidney function: neutrophil count = 1500 cells / mm3; platelet count = 70000 / mm3; hemoglobin (Hgb) = 8.0 g / dl; if there is liver metastasis, AST and ALT < 3x ULN 10. The interval between systemic chemotherapy is more than 2 weeks, and the side effects recovery from previous treatment = grade 1 11. Patients receiving bisphosphonates, endocrine or targeted therapy at the same time were not included Exclusion Criteria: 1. Patients with mechanically unstable spine or epidural spinal cord compression were excluded; however, patients with previously documented spinal cord compression that had been decompressed and stabilized were eligible. Patients with > 50% loss of vertebral body height were excluded. 2. Patients in whom a delay in initiating treatment might have adversely affected neurological outcome. 3. Patients with a pacemaker, unable to undergo MR imaging and unable to lie flat for at least 30 minutes. 4. Patients who had a history of previous radiotherapy to the spine at the current level of interest. 5. Patients who had received prior external-beam irradiation to the spine within 3 months of registration. 6. Patients who had received systemic radiotherapy (Strontium-89) within 30 days of starting protocol treatment. 7. Patients who had received chemotherapy within 2 weeks of starting protocol treatment. 8. Patients who are unwilling or unable to receive regular follow-up. 9. The patients judged by the researchers who could not be included in some special cases. 10. Serious complications: cardiovascular disease, end-stage renal disease, serious liver disease, infection, et al. 11. Pregnant women.

Study Design


Intervention

Radiation:
Fractionated Stereotatic Radiation Therapy
Participants prescribed to receive 9 Gy x 3 or 10 Gy x3 image-guided fractionated stereotatic radiation therapy.

Locations

Country Name City State
China Fudan University Shanghai Cancer Center Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Local Control Rate Determine the local control rate of FSRT in patients with bone metastasis of breast cancer 3 years
Secondary Pain Control Evaluate whether FSRT improves pain control as measured by Brief Pain Inventory (BPI) after FSRT in patients with spinal metastasis of breast cancer 3 years
Secondary Overall Survival Time from the date of informed consent until to the date of death, regardless of the cause of death 3 years
Secondary Progression Free Survival Time from the date of radiotherapy to the investigator-determined date of progression or death due to any cause, whichever occurs first 3 years
Secondary Quality of Life Evaluate the quality of life according to EORTC QLQ-BM22 3 years
Secondary Vertebral Fracture and Radiation Myelitis Determine the incidence of bone fracture and radiation myelitis 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A